(GLUE) Monte Rosa Therapeutics - Ratings and Ratios
MRT-2359, MRT-6160, MRT-8102, CDK2 Inhibitor
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 116% |
| Value at Risk 5%th | 169% |
| Relative Tail Risk | -11.96% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.94 |
| Alpha | 47.20 |
| CAGR/Max DD | 0.32 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.401 |
| Beta | 1.062 |
| Beta Downside | 0.248 |
| Drawdowns 3y | |
|---|---|
| Max DD | 73.63% |
| Mean DD | 38.24% |
| Median DD | 38.91% |
Description: GLUE Monte Rosa Therapeutics October 28, 2025
Monte Rosa Therapeutics (NASDAQ: GLUE) is a clinical-stage biotech focused on orally bioavailable “molecular glue degraders” (MGDs) that co-opt the body’s ubiquitin-proteasome system to eliminate disease-relevant proteins. Its lead candidates include MRT-2359 (targeting MYC-driven cancers), MRT-6160 (neurologic and systemic autoimmune/inflammatory disorders), and MRT-8102 (IL-1β/NLRP3-driven inflammation), plus a CDK2-directed oncology program covering ovarian, endometrial, gastric and breast cancers. The firm also operates the QuEEN discovery engine to accelerate target-centric MGD design and maintains a strategic partnership with F. Hoffmann-La Roche for joint MGD discovery in oncology and neurology.
As of the most recent 10-Q (Q2 2024), Monte Rosa reported cash and cash equivalents of roughly $115 million, giving it an estimated 12-month runway at its current burn rate of ~$9 million per quarter. The protein-degradation market is projected to grow at a CAGR of 25-30 % through 2030, driven by the therapeutic promise of targeting “undruggable” proteins-a macro-trend that underpins Monte Rosa’s value proposition. The company’s collaboration with Roche includes an upfront payment of $30 million and potential milestone payments exceeding $300 million, which could materially de-risk its cash position if key pre-clinical milestones are met.
For a deeper, data-driven look at Monte Rosa’s valuation and risk profile, the ValueRay platform’s analyst notes provide a useful next step.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (20.9m TTM) > 0 and > 6% of Revenue (6% = 10.9m TTM) |
| FCFTA 0.32 (>2.0%) and ΔFCFTA 51.46pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 187.5% (prev 883.2%; Δ -695.7pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.32 (>3.0%) and CFO 149.1m > Net Income 20.9m (YES >=105%, WARN >=100%) |
| Net Debt (-168.2m) to EBITDA (19.6m) ratio: -8.60 <= 3.0 (WARN <= 3.5) |
| Current Ratio 6.54 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (82.4m) change vs 12m ago 0.47% (target <= -2.0% for YES) |
| Gross Margin 96.54% (prev 66.68%; Δ 29.86pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 46.85% (prev 7.53%; Δ 39.32pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1.05 (EBITDA TTM 19.6m / Interest Expense TTM -10.7m) >= 6 (WARN >= 3) |
Altman Z'' -0.14
| (A) 0.74 = (Total Current Assets 401.8m - Total Current Liabilities 61.4m) / Total Assets 459.8m |
| (B) -0.94 = Retained Earnings (Balance) -431.1m / Total Assets 459.8m |
| (C) 0.03 = EBIT TTM 11.2m / Avg Total Assets 387.5m |
| (D) -2.03 = Book Value of Equity -434.3m / Total Liabilities 214.0m |
| Total Rating: -0.14 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 71.38
| 1. Piotroski 5.50pt |
| 2. FCF Yield 21.01% |
| 3. FCF Margin 79.89% |
| 4. Debt/Equity 0.16 |
| 5. Debt/Ebitda -8.60 |
| 6. ROIC - WACC (= -5.67)% |
| 7. RoE 8.28% |
| 8. Rev. Trend 86.02% |
| 9. EPS Trend 66.62% |
What is the price of GLUE shares?
Over the past week, the price has changed by +5.44%, over one month by +39.69%, over three months by +237.20% and over the past year by +70.99%.
Is GLUE a buy, sell or hold?
- Strong Buy: 6
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the GLUE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.2 | 2% |
| Analysts Target Price | 17.2 | 2% |
| ValueRay Target Price | 18.1 | 7.2% |
GLUE Fundamental Data Overview November 29, 2025
P/E Trailing = 49.9688
P/E Forward = 10.02
P/S = 5.7356
P/B = 4.2381
Beta = 1.62
Revenue TTM = 181.5m USD
EBIT TTM = 11.2m USD
EBITDA TTM = 19.6m USD
Long Term Debt = 40.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.24m USD (from shortTermDebt, last quarter)
Debt = 40.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -168.2m USD (from netDebt column, last quarter)
Enterprise Value = 690.1m USD (1.04b + Debt 40.2m - CCE 391.3m)
Interest Coverage Ratio = -1.05 (Ebit TTM 11.2m / Interest Expense TTM -10.7m)
FCF Yield = 21.01% (FCF TTM 145.0m / Enterprise Value 690.1m)
FCF Margin = 79.89% (FCF TTM 145.0m / Revenue TTM 181.5m)
Net Margin = 11.54% (Net Income TTM 20.9m / Revenue TTM 181.5m)
Gross Margin = 96.54% ((Revenue TTM 181.5m - Cost of Revenue TTM 6.28m) / Revenue TTM)
Gross Margin QoQ = 83.59% (prev 90.84%)
Tobins Q-Ratio = 1.50 (Enterprise Value 690.1m / Total Assets 459.8m)
Interest Expense / Debt = 2.33% (Interest Expense 935.0k / Debt 40.2m)
Taxrate = 10.50% (-3.18m / -30.3m)
NOPAT = 10.0m (EBIT 11.2m * (1 - 10.50%))
Current Ratio = 6.54 (Total Current Assets 401.8m / Total Current Liabilities 61.4m)
Debt / Equity = 0.16 (Debt 40.2m / totalStockholderEquity, last quarter 245.8m)
Debt / EBITDA = -8.60 (Net Debt -168.2m / EBITDA 19.6m)
Debt / FCF = -1.16 (Net Debt -168.2m / FCF TTM 145.0m)
Total Stockholder Equity = 253.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.56% (Net Income 20.9m / Total Assets 459.8m)
RoE = 8.28% (Net Income TTM 20.9m / Total Stockholder Equity 253.0m)
RoCE = 3.83% (EBIT 11.2m / Capital Employed (Equity 253.0m + L.T.Debt 40.2m))
RoIC = 3.97% (NOPAT 10.0m / Invested Capital 253.0m)
WACC = 9.64% (E(1.04b)/V(1.08b) * Re(9.93%) + D(40.2m)/V(1.08b) * Rd(2.33%) * (1-Tc(0.10)))
Discount Rate = 9.93% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 20.31%
[DCF Debug] Terminal Value 62.44% ; FCFE base≈145.0m ; Y1≈95.2m ; Y5≈43.5m
Fair Price DCF = 9.91 (DCF Value 645.6m / Shares Outstanding 65.1m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 66.62 | EPS CAGR: 91.92% | SUE: 0.07 | # QB: 0
Revenue Correlation: 86.02 | Revenue CAGR: 331.7% | SUE: 0.21 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.47 | Chg30d=+0.015 | Revisions Net=+0 | Analysts=4
EPS next Year (2026-12-31): EPS=-1.42 | Chg30d=-0.129 | Revisions Net=-1 | Growth EPS=-599.8% | Growth Revenue=-62.3%
Additional Sources for GLUE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle